ClinicalTrials.gg
RecruitingNCT07809763Updated Sep 9, 2026

Wireless Wearable Home Prehabilitation for Older Adults With NSCLC

An interventional study of Digital Home-Based Prehabilitation and Standard Perioperative Care in Non-Small Cell Lung Cancer (NSCLC), Rehabilitation and Thoracic Surgery, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by West China Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital — 14 open to participants now, 14 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · West China Hospital.

Planned enrollment
5th of 15
196 · median 82
Started
2026
with 8 others
No phase
6 of 18
6 open now
Primary completion
2028-07
later than 8 of 13 live
Registered
14th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 9 that started in 2026, is one of 6 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital, or all of them as a file.
02

Study summary

This randomized controlled trial evaluates the efficacy and safety of a home-based prehabilitation program using wireless wearable monitoring devices in older patients (aged 65-85 years) with non-small cell lung cancer scheduled for curative lung resection. Participants are randomized 1:1 to either the intervention group, receiving a personalized exercise regimen (aerobic, resistance, and inspiratory muscle training) with continuous remote monitoring of steps, heart rate, and SpO₂ from 2-4 weeks preoperatively through 90 days postoperatively, or the control group receiving standard perioperative care. The primary endpoint is the between-group difference in FEV₁% predicted at 90 days post-surgery, adjusted for baseline. Secondary endpoints include functional capacity (6-minute walk distance), daily physical activity, hypoxemic burden (time with SpO₂\<90%, nocturnal oxygen desaturation index), patient-reported outcomes (EORTC QLQ-C30/LC13, mMRC), postoperative complications, readmission rates, days alive and at home, and safety outcomes. The target sample size is 198 participants enrolled at West China Hospital of Sichuan University. Anticipated risks include exercise-related musculoskeletal strain, fatigue, and transient cardiopulmonary symptoms, as well as mild skin reactions from devices, all managed through individualized exercise prescriptions, remote safety thresholds, and a graded response protocol.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
  • Rehabilitation
  • Thoracic Surgery
  • Prehabilitation

Keywords

  • Non-Small Cell Lung Cancer (NSCLC)
  • Rehabilitation
  • Thoracic Surgery
  • Prehabilitation
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥65 and ≤85 years
  • Histopathologically confirmed primary non-small cell lung cancer (NSCLC), scheduled for elective curative-intent lobectomy or segmentectomy
  • (ECOG) performance status 0-2, or Performance Status (KPS) score ≥70
  • Planned admission for surgery within 2 months, and judged by the investigator to have stable disease suitable for participation in a home-based rehabilitation program
  • Able to operate a smartphone application and wearable devices independently or with caregiver assistance
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Pre-existing long-term home oxygen therapy, or severe resting respiratory dysfunction
  • Concurrent severe, uncontrolled cardiovascular disease, hepatic insufficiency, or renal insufficiency
  • Other diseases that seriously affect motor function or compliance
  • Known or suspected contact allergy to medical adhesives or materials used in the wearable devices
  • Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    Wearable-Based Home Prehabilitation

    Participants receive a wireless wearable monitoring system (smartwatch/ring and fingertip pulse oximeter) to continuously track steps, moderate-to-vigorous physical activity, heart rate, SpO₂, and sleep. A personalized home-based exercise program is prescribed, including moderate-intensity aerobic exercise (≥5 days/week, 30-45 min/session), inspiratory muscle training (twice daily), and functional/chest expansion exercises, starting 2-4 weeks before surgery and continuing until 90 days postoperatively. Remote monitoring with automated safety alerts (e.g., SpO₂\<90% for ≥5 min, step count drop ≥40%) triggers a graded response protocol. Participants also receive nutritional guidance, smoking cessation advice, and complication education. All interventions are delivered via a digital health platform with regular remote follow-up.

    Behavioral: Digital Home-Based Prehabilitation

  • Active comparator
    Standard Perioperative Care

    Participants receive the institution's standard enhanced recovery after surgery (ERAS) pathway, including routine preoperative education, postoperative physical therapy (chest physiotherapy, early mobilization), and standard nursing care. They do not receive the wearable monitoring devices, the structured remote exercise prescription, or the continuous digital supervision. The frequency and content of follow-up visits are identical to those of the intervention group for outcome assessment purposes, but no programmatic home prehabilitation or remote monitoring is provided.

    Behavioral: Standard Perioperative Care

Interventions

  • BehavioralDigital Home-Based Prehabilitation

    A home-based multimodal prehabilitation and rehabilitation program delivered via a digital health platform, supported by wireless wearable monitoring devices (smartwatch/ring and fingertip pulse oximeter). The intervention includes: (1) moderate-intensity aerobic exercise (≥5 days/week, 30-45 min/session, Borg scale 3-4), (2) inspiratory muscle training (twice daily), (3) functional and chest expansion exercises, and (4) nutritional guidance, smoking cessation advice, and complication education. The program starts 2-4 weeks preoperatively and continues through 90 days post-surgery. Continuous remote monitoring of steps, heart rate, SpO₂, and activity levels with automated safety alerts (e.g., SpO₂\<90% for ≥5 min, step drop ≥40%) triggers a graded clinical response. Participants receive regular remote follow-up and individualized exercise adjustments based on real-time data.

  • BehavioralStandard Perioperative Care

    Participants receive the institution's standard enhanced recovery after surgery (ERAS) pathway, including routine preoperative education, postoperative chest physiotherapy, early mobilization guidance, and standard nursing care. No wearable monitoring devices, structured remote exercise prescriptions, digital health platform, or continuous remote supervision are provided. Follow-up visits are scheduled at the same time points as the intervention group for outcome assessment, but no programmatic home-based prehabilitation or tele-monitoring is delivered.

06

What researchers measure

Primary outcomes

  1. FEV₁% Predicted at 90 Days Post-Surgery

    Forced expiratory volume in 1 second as a percentage of the predicted value, measured by spirometry according to ATS/ERS standards. The measurement is taken at the 90-day (±14 days) follow-up visit. The primary analysis compares the adjusted between-grou

    Time frame: 90 days after surgery (±14 days)

Secondary outcomes

  1. Change From Baseline in FVC Percent Predicted

    Forced vital capacity measured by spirometry according to ATS/ERS standards and expressed as a percentage of the predicted value. Change from the preoperative baseline value will be determined at 30 and 90 days after surgery.

    Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days

  2. Change From Baseline in FEV1/FVC Ratio

    The ratio of forced expiratory volume in 1 second to forced vital capacity, measured by spirometry according to ATS/ERS standards. Change from the preoperative baseline value will be determined at 30 and 90 days after surgery.

    Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days

  3. Change From Baseline in 6-Minute Walk Distance

    Distance walked during a 6-minute walk test performed on a flat, marked course according to ATS guidelines. Change from the preoperative baseline distance will be determined at 30 and 90 days after surgery.

    Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days

  4. Change in Borg Dyspnea Score During the 6-Minute Walk Test

    Borg dyspnea scores will be recorded immediately before and immediately after each 6-minute walk test. The outcome is calculated as the post-test score minus the pre-test score.

    Time frame: Baseline, 30 days after surgery with an allowable window of ±7 days, and 90 days after surgery with an allowable window of ±14 days

  5. Mean Daily Step Count

    The mean number of steps per day recorded by the wearable device. For the intervention group, step count will be recorded throughout the intervention period. For the control group, step count will be recorded during protocol-specified 7-day assessment periods. Daily values will be averaged across valid wear days, defined as days with at least 10 hours of wear time.

    Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90

  6. Mean Daily Moderate-to-Vigorous Physical Activity

    The mean duration of moderate-to-vigorous physical activity recorded by the wearable device. For the intervention group, activity will be recorded throughout the intervention period. For the control group, activity will be recorded during protocol-specified 7-day assessment periods. Values will be averaged across valid wear days, defined as days with at least 10 hours of wear time.

    Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90

  7. Percentage of Monitoring Time With SpO2 Below 90%

    The percentage of valid pulse-oximetry monitoring time during which peripheral oxygen saturation is below 90%, calculated from continuous or minute-level SpO2 recordings.

    Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90

  8. Nocturnal Oxygen Desaturation Index

    The mean number of nocturnal oxygen desaturation events per hour of valid overnight recording. An oxygen desaturation event is defined as a decrease in SpO2 of at least 3% from the preceding baseline level.

    Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90

  9. Change From Baseline in EORTC QLQ-C30 Score

    Health-related quality of life assessed using the EORTC QLQ-C30 Global Health Status/Quality of Life scale. Scores are transformed to a 0-100 scale according to the EORTC scoring manual, with higher scores indicating better global health status and quality of life. Change from the preoperative baseline score will be determined at 30 and 90 days after surgery.

    Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days

  10. Change From Baseline in EORTC QLQ-LC13 Score

    Lung cancer-related symptoms assessed using the prespecified EORTC QLQ-LC13 scale or item. Scores will be calculated according to the EORTC scoring manual and transformed to a 0-100 scale. Change from the preoperative baseline score will be determined at 30 and 90 days after surgery. The direction of a higher score should be stated for the selected scale or item.

    Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days

  11. Change From Baseline in mMRC Dyspnea Scale Score

    Dyspnea assessed using the modified Medical Research Council scale, ranging from 0 to 4, with higher scores indicating greater dyspnea-related functional limitation. Change from the preoperative baseline score will be determined at 30 and 90 days after surgery.

    Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days

  12. Incidence of All-Cause Hospital Readmission Within 90 Days

    Percentage of participants who have at least one unplanned hospital readmission for any cause during the first 90 days after surgery.

    Time frame: Within 90 days after surgery

  13. Incidence of Emergency Department Visits Within 90 Days

    Percentage of participants who have at least one emergency department visit for any cause during the first 90 days after surgery.

    Time frame: Within 90 days after surgery

  14. Incidence of Postoperative Pulmonary Complications Within 90 Days

    Percentage of participants who experience at least one postoperative pulmonary complication meeting the protocol-specified EPCO or CHEST criteria. Pulmonary complications include pneumonia, respiratory failure or re-intubation, atelectasis requiring intervention, acute respiratory distress syndrome, pleural effusion requiring drainage, bronchospasm requiring treatment, or pulmonary embolism. Each participant will be counted once regardless of the number of complications experienced.

    Time frame: Within 90 days after surgery

  15. Days Alive and at Home During the First 90 Days After Surgery

    Number of days during the first 90 postoperative days that the participant is alive and not admitted to a hospital, rehabilitation facility, or other inpatient institutional care facility. The value is calculated as 90 minus the total number of days spent in hospital or institutional care. Participants who die within 90 days after surgery will be assigned a value of zero days.

    Time frame: Within 90 days after surgery

  16. Incidence of Adverse Events

    Percentage of participants who experience at least one adverse event after providing informed consent. Adverse events will be identified and graded according to CTCAE version 5.0. Events of special interest include exercise-related, wearable-device-related, and oxygen-related adverse events. Each participant will be counted once regardless of the number of adverse events experienced.

    Time frame: From signing informed consent through 90 days after surgery

  17. Incidence of Serious Adverse Events

    Percentage of participants who experience at least one serious adverse event after providing informed consent. Serious adverse events will be classified and graded according to the protocol and CTCAE version 5.0. Each participant will be counted once regardless of the number of serious adverse events experienced.

    Time frame: From signing informed consent through 90 days after surgery

Other outcomes

  1. Wearable-Device Adherence Rate

    Percentage of observed days on which the wearable device is worn for at least 12 hours. The numerator is the number of days meeting the required wear-time threshold, and the denominator is the total number of expected observation days.

    Time frame: From baseline through 90 days after surgery

  2. Exercise Prescription Completion Rate

    Percentage of prescribed exercise sessions completed by participants in the intervention group. The numerator is the number of completed prescribed sessions, and the denominator is the total number of prescribed sessions during the intervention period.

    Time frame: From baseline through 90 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2028, 22 months later.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 22 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Sep 9, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07809763
Responsible party
Xuelei Ma MD (Clinical Professor, West China Hospital) — Principal investigator
First posted
Sep 9, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Xuelei Ma, MD
Contact
linnan@stu.scu.edu.cn
18708305692

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion